WEKO3
-
RootNode
アイテム
Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression
http://hdl.handle.net/10458/0002000385
http://hdl.handle.net/10458/00020003850d9ac936-2582-43f1-ae47-46d0e06a42d4
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2023-12-18 | |||||
タイトル | ||||||
タイトル | Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
キーワード | Caveolin-1 | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
キーワード | caveolin-2 | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
キーワード | prostate cancer progression | |||||
資源タイプ | ||||||
資源タイプ | journal article | |||||
著者 |
杉江, 悟
× 杉江, 悟× 向井, 尚一郎× 山崎, 浩司× 上別府, 豊治× 月野, 浩昌× 賀本, 敏行 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background/Aim: Up-regulation of caveolin (CAV)-1 is associated with aggressive prostate cancer. Recently, it has been inferred that CAV2, a co-factor sub-type of CAV1, cross-talks with CAV1 and promotes tumor growth. We previously reported that plasma CAV1 levels are elevated in patients with castration-resistant prostate cancer (CRPC), but not in hormone-sensitive prostate cancer (non-CRPC), implying that CAV1 may be a therapeutic target for CRPC. However, a correlation of CAV1 and CAV2 expression in PC has not yet been reported. Herein, we analyzed associations between PC progression and plasma CAV1 and -2 in Japanese men, and expression of CAV1 and -2 in PC3 (CRPC) and LNCaP (non-CRPC) cell lines. Materials and Methods: We investigated plasma samples from 36 patients with CRPC and 22 with non-CRPC. We used enzyme-linked immunosorbent assay (ELISA) to determine plasma levels of CAV1 and -2, and examined correlations with clinicopathological characteristics such as Gleason grade and clinical T stage. Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to evaluate CAV1 and CAV2 mRNA in PC cell lines. We also introduced CAV1- and CAV2-specific small interfering (siRNA) into PC3 cells to knock-down (KD) both molecules, and examined its influence on the expression of these genes between PC3 CAV1 and -2 KD cells and control cells. Results: Plasma CAV1 and -2 levels in patients with CRPC were significantly higher than in those with non-CRPC (CAV1, p=0.003; CAV2, p<0.001). Plasma levels of CAV1 and -2 were significantly correlated (p<0.001). However, we did not find any significant relationship between CAV1 or CAV2 expression and clinicopathological factors. ELISA and real-time qRT-PCR showed that both proteins and mRNAs in PC3 cells were significantly over-expressed compared to LNCaP cells (p<0.001). In PC3 CAV1 KD cells, expression of CAV2 was suppressed and confirmed the linkage of CAV2 KD and suppression of CAV1 expression. Conclusion: There was a significant correlation between plasma CAV-1 and -2 levels and progression of PC. CAV1 and -2 were highly expressed in the PC3 compared to the LNCaP cell line. Our findings support the potential of these molecules as therapeutic targets for CRPC. | |||||
言語 | en | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Citation: Sugie S, Mukai S, Yamasaki K, Kamibeppu T, Tsukino H, Kamoto T. Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):391-6. PMID: 26543085. |
|||||
言語 | en | |||||
書誌情報 |
en : Cancer Genomics Proteomics 巻 12, 号 6, p. 391-396 |
|||||
出版者 | ||||||
出版者 | Cancer & Genome Proteomics | |||||
言語 | en | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1109-6535 | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | Copyright© 2015, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved | |||||
著者版フラグ | ||||||
出版タイプ | VoR |
Share
Cite as
杉江, 悟, 向井, 尚一郎, 山崎, 浩司, 上別府, 豊治, 月野, 浩昌, 賀本, 敏行, n.d., Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression: Cancer & Genome Proteomics, 391–396 p.
Loading...